As the first Southeast Asian generic option for the originator drug Mobocertinib, the Laos Dabear version of Mobocertinib brings new hope to patients with advanced lung cancer carrying EGFR exon 20 insertion mutations, with validated efficacy and lower treatment costs.
What are the purchasing channels for the Laos Dabear version of Mobocertinib?
The Laos Dabear version of Mobocertinib is available in the specification of 40mg*112 capsules/box. For specific purchasing methods, it is recommended that you contact professional customer service for detailed consultation.
Mobocertinib indications and recommended dosage regimen
The indication for Mobocertinib is: for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test, whose disease has progressed during or after platinum-based chemotherapy. Regarding the recommended dosage, the usual dose of Mobocertinib is 160 mg taken orally once daily. Patients should continue treatment until disease progression or unacceptable toxicity occurs. The daily dose should be taken at approximately the same time each day, with or without food. Capsules must be swallowed whole; do not open, chew, or dissolve the capsule contents. If a patient misses a dose and more than 6 hours have passed, the missed dose should be skipped and the next dose taken at the regularly scheduled time the following day. If vomiting occurs after taking a dose, do not take an additional dose; instead, wait until the next day to take the next dose at the regular time. This dosage regimen is based on efficacy and safety data from clinical studies, designed to balance antitumor activity and adverse reaction management.
Mobocertinib adverse reactions and use in special populations
Adverse reactions shown in clinical studies of Mobocertinib mainly include: the most common (incidence >20%) adverse reactions are diarrhea, rash, nausea, stomatitis, vomiting, decreased appetite, paronychia, fatigue, dry skin, and musculoskeletal pain. In terms of laboratory abnormalities, the most common (≥2%) grade 3 or 4 abnormalities include decreased lymphocytes, elevated amylase, elevated lipase, hypokalemia, decreased hemoglobin, elevated creatinine, and hypomagnesemia. Regarding use in special populations: Mobocertinib may cause fetal harm when administered to pregnant women; use is not recommended. Breastfeeding women should not breastfeed during treatment and for 1 week after the last dose. The safety and efficacy in pediatric patients have not been established. The incidence of grade 3-4 adverse reactions and serious adverse reactions in elderly patients (aged 65 years and older) is higher than in younger patients. No dose adjustment is required for patients with mild to moderate renal impairment; the recommended dose for patients with severe renal impairment has not been established. No dose adjustment is required for patients with mild to moderate hepatic impairment; the recommended dose for patients with severe hepatic impairment has not been established. A comprehensive assessment of patient status is required before treatment.
